NEW YORK (GenomeWeb) – CompanionDx, a high-complexity CLIA-certified laboratory, announced on Monday that it will expand its next-generation sequencing (NGS) offerings with two of Thermo Fisher Scientific cancer assays. 

CompanionDx said it will provide the Oncomine Focus Assay and the Oncomine Comprehensive Assay to clients performing studies across a range of different cancer types. The deal creates new NGS services that could be used in combination with pharmacogenomics to facilitate drug development and clinical research program by drug manufacturers, CompanionDx said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sep
07
Sponsored by
PerkinElmer

This webinar will address improvements in the library prep workflow for small RNA sequencing in serum and plasma.

Sep
20
Sponsored by
Ion Torrent

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21
Sponsored by
Roche

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
26
Sponsored by
PerkinElmer

This webinar will describe a protocol and proof-of-principle experiments for Cellular Indexing of Transcriptome and Epitopes by Sequencing (CITE-seq).